BFRI Announces Positive Phase 3 Results for Ameluz® PDT, Achieving 45.6% Complete Clearance Rate, Plans sNDA Submission Q3 2026
Biofrontera Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $0.95
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS